Buscar
Drugs Made In America Acquisition Corp
DMAAAñadir a la lista de seguimiento
10.585USD
-0.005-0.05%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
256.97MCap. mercado
73.43P/E TTM
Más Datos de Drugs Made In America Acquisition Corp Compañía
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.
Información de Drugs Made In America Acquisition Corp
Símbolo de cotizaciónDMAA
Nombre de la empresaDrugs Made In America Acquisition Corp
Fecha de salida a bolsaJan 28, 2025
Director ejecutivoStockwell (Lynn)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 28
Dirección1 East Broward Boulevard
CiudadFT LAUDERDALE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33301
Teléfono19548703099
Sitio Web
Símbolo de cotizaciónDMAA
Fecha de salida a bolsaJan 28, 2025
Director ejecutivoStockwell (Lynn)
Ejecutivos de Drugs Made In America Acquisition Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 7 de may
Actualizado: jue., 7 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Drugs Made In America Acquisition LLC
12.42%
Karpus Investment Management
7.53%
First Trust Capital Management L.P.
6.65%
Mizuho Securities USA, LLC.
5.93%
Glazer Capital, LLC
5.39%
Otro
62.08%
Accionistas
Accionistas
Proporción
Drugs Made In America Acquisition LLC
12.42%
Karpus Investment Management
7.53%
First Trust Capital Management L.P.
6.65%
Mizuho Securities USA, LLC.
5.93%
Glazer Capital, LLC
5.39%
Otro
62.08%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
30.86%
Investment Advisor/Hedge Fund
23.94%
Corporation
12.42%
Investment Advisor
8.51%
Research Firm
5.68%
Individual Investor
0.89%
Otro
17.70%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
54
23.26M
68.99%
-2.07M
2025Q4
47
22.21M
67.76%
-8.45K
2025Q3
47
22.22M
67.76%
+1.02M
2025Q2
38
21.21M
54.90%
+2.81M
2025Q1
25
18.33M
0.00%
+18.33M
2024Q4
5
4.59M
15.73%
+4.59M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Drugs Made In America Acquisition LLC
8.57M
25.57%
+4.38M
+104.63%
Feb 25, 2025
Karpus Investment Management
2.54M
7.57%
-9.03K
-0.35%
Dec 31, 2025
First Trust Capital Management L.P.
2.24M
6.69%
--
--
Dec 31, 2025
Mizuho Securities USA, LLC.
1.43M
4.28%
+333.04K
+30.26%
Dec 31, 2025
Glazer Capital, LLC
1.82M
5.42%
-5.86K
-0.32%
Dec 31, 2025
Westchester Capital Management, LLC
1.67M
4.98%
--
--
Dec 31, 2025
Polar Asset Management Partners Inc.
1.60M
4.77%
-300.00K
-15.79%
Dec 31, 2025
Wolverine Asset Management, LLC
1.31M
3.9%
+58.34K
+4.67%
Dec 31, 2025
Hudson Bay Capital Management LP
1.55M
4.62%
--
--
Dec 31, 2025
Aristeia Capital, L.L.C.
881.72K
2.63%
--
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
CrossingBridge Pre-Merger SPAC ETF
0%
CrossingBridge Pre-Merger SPAC ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
